Type of Mesothelioma:
Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells
Cellular Oncology 2026 June 8 [Link] Eleonora Nigliato, Yan Ma, Rita Derua, Maria Butyrin, Sandra P Nunes, Léa Guilmot, Antonio De Gianni, Rüveyda Dok, Andrew P Feld, Michael Ohlmeyer, Brian E Wadzinski, Sandra Nuyts, Ilaria Elia, Anna Sablina, Veerle Janssens Abstract Purpose: Malignant pleural mesothelioma (MPM) is a rare cancer of the pleura, frequently related…
Read MoreA single-center experience in parenchyma-sparing surgical treatment of malignant pleural mesothelioma
Updates in Surgery 2026 June 1 [Link] Giuseppe Mangiameli, Debora Brascia, Emanuela Re Cecconi, Veronica Maria Giudici, Edoardo Bottoni, Alessandro Crepaldi, Umberto Cariboni, Alberto Testori, Paolo Zucali, Matteo Perrino, Nadia Cordua, Armando Santoro, Marco Alloisio, Giuseppe Marulli Abstract The role of surgery in malignant pleural mesothelioma (MPM) remains controversial, particularly after the negative results of…
Read MoreConditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma
Scientific Reports 2026 June 1 [Link] Xiaofeng Liao, Chen Li, Ming Huang, Zheng Yao, Shikun Luo, Xiaoyu Lei Abstract Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer with limited treatment options and extremely poor survival outcomes. Due to the disease’s low incidence, large-scale cohort studies to clarify survival outcomes and the impact of treatments…
Read MoreLocalised malignant mesothelioma presenting as an esophageal mass: An unusual manifestation
Radiology Case Reports 2026 May 19 [Link] Kaspar L Yaxley, Tristan Rutland, Thisuri Jayawardena, David Law, Yuranga Weerakkody Abstract Malignant mesothelioma is an aggressive neoplasm arising from mesothelial cells, typically presenting with pleural thickening, pleural effusions, or respiratory symptoms. Dysphagia as a presenting symptom is extremely uncommon, and esophageal involvement is rare. We report a…
Read MoreFeasibility and Outcomes of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 May 28 [Link] Yota Suzuki, Inderpal S Sarkaria, Edra Ha, Ian G Christie, Olugbenga T Okusanya, Omar Awais, Evan T Alicuben, Ryan M Levy, James D Luketich, Neil A Christie Abstract Background: The management of pleural mesothelioma requires a multidisciplinary approach, and hyperthermic intrathoracic chemoperfusion (HITHOC) after surgical cytoreduction…
Read MoreA High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma
Cancers 2026 May 7 [Link] Zivile Useckaite, Ashleigh J Hocking, Lauren A Mortimer, John Salamon, Simon Lee, Yazad Irani, Lucy Franzon, Arya L Arul, Sarita Prabhakaran, Sonja Klebe Abstract Background: Pleural mesothelioma (PM) is characterised by often rapid therapeutic failure and chemotherapy resistance. While terminal resistance is well studied, the initial transition into a drug-tolerant…
Read MoreQuercetin-Arctigenin Co-Treatment Induces Mitochondrial Dysfunction and Apoptotic Cell Death Through Metabolic Stress in Malignant Mesothelioma Cells
Life 2026 May 6 [Link] Moon-Kyun Cho, Sang-Han Lee, Hae-Seon Nam, Yoon-Jin Lee Abstract Malignant mesothelioma is an aggressive cancer with limited therapeutic options, highlighting the need for novel strategies targeting metabolic vulnerabilities. Natural polyphenols have gained attention due to their ability to modulate cellular metabolism and apoptosis-related signaling pathways. In this study, we investigated…
Read MoreIncreased Toll-like receptor 9 expression associated with cellular proliferation and poor prognosis in pleural mesothelioma
Journal of Pathology and Translational Medicine 2026 July [Link] Ali Omar Abdelaziz, Dina Moustafa Thabit, Rehab Mohamed Kamal, Hend Moness, Rasha Fouad Ahmed, Mariana Fathy Gayyed, Fatma El Zahraa Ammar Mohamed Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The epithelioid subtype is the most common and can be challenging to…
Read MoreThe role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy
Lung Cancer 2026 July [Link] Farhad Kosari, Paul Baas, Maria Disselhorst, Kim Lauer, Tobias Peikert, Stephen Murphy, Janet Schaefer Klein, Aaron S Mansfield Abstract Assessing the contributions of microRNAs to gene expression regulation and treatment outcomes in malignancies is challenging. Traditional analyses focus on individual microRNAs, overlooking competitive binding among RNA species sharing common microRNAs.…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read More
Skip to content